NCT02912572: Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 106 taking part
- Started
- 14 Nov 2016
- Primary completion
- 15 Nov 2023
- Arms
- Pole Mutated Endometrial Cancer, MSS Endometrial Cancer
- Results
- Posted on the registry
- 23 Sep 2016: Trial registered
- 14 Nov 2016: Trial started
- 5 Jul 2024: Trial results posted